Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma,...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Target Price
The average target price of DRTS is 8.0 and suggests 6% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation su
Buy
Sell